Study wrapper · #968
Synthetic target trial emulation and predictive modeling of amylin-pathway therapies for obesity and type 2 diabetes.
Al-Harbi FA, Alsaif AK, Almutairi AG, et al. Metabolism open. 2025.
DOI: 10.1016/j.metop.2025.100414PubMed: 41255585
Editor's note
A network meta-analysis and computational modeling exercise drawing on seven RCTs (5,786 participants) of amylin-pathway agents including cagrilintide and CagriSema. Findings are model-derived predictions rather than direct trial outcomes, so results should be read as hypothesis-generating. Relevant to the amylin drug class.
Plain-language abstract
This modeling study pooled seven trials of amylin-pathway therapies, including CagriSema and cagrilintide, to simulate comparative effectiveness for obesity and type 2 diabetes.
Related coverage
Mixed
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Lancet (London, England)n=——2026
Supported
Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
The lancet. Diabetes & endocrinologyn=——2026
Supported
Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
Lancet (London, England)n=——2026